• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Fresenius

Fresenius Kabi to acquire Ivenix and its smart infusion system for $240M upfront

March 31, 2022 By Sean Whooley

Fresenius Kabi Ivenix

Fresenius Kabi announced today that it will acquire Ivenix with plans to bring a comprehensive infusion product portfolio to the U.S. The acquisition, which has a purchase price of $240 million upfront, also includes potential milestone payments linked to achievements of commercial and operating targets. According to a news release, the companies expect the acquisition […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals Tagged With: Fresenius, freseniuskabi, Ivenix, mAbxience

Del. supremes uphold Fresenius bailout on Akorn buy

December 10, 2018 By Sarah Faulkner

Fresenius Kabi logo updated

Delaware’s Supreme Court ruled last week to uphold a decision by the state’s Chancery Court that Fresenius (ETR:FRE) could walk away from its $4 billion merger with Akorn (NSDQ:AKRX). The initial deal was designed to help Fresenius move into new therapeutic areas and dosage forms, including eye drugs, ear drops, nasal sprays and respiratory drugs. But Fresenius abandoned the […]

Filed Under: Business/Financial News, Featured, Legal News, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Akorn, Fresenius

Fresenius cleared to jilt Akorn, court rules

October 2, 2018 By Sarah Faulkner

Fresenius Kabi logo updated

The Delaware Chancery Court ruled this week that it can’t force Fresenius (ETR:FRE) to follow through with its $4.75 billion merger with Akorn (NSDQ:AKRX). The deal was designed to help Fresenius move into new dosage forms and therapeutic areas, including ophthalmic drugs, ear drops, nasal sprays and respiratory drugs. But Fresenius walked away from the deal in April, […]

Filed Under: Drug-Device Combinations, Featured, Legal News, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Akorn, Fresenius

Fresenius fires back at Akorn with counterclaims following failed merger

May 3, 2018 By Sarah Faulkner

Fresenius Kabi

Fresenius (ETR:FRE) filed counterclaims against generic drugmaker Akorn Inc. (NSDQ:AKRX) this week in Delaware Chancery Court, alleging that Akorn tried to defraud the FDA with falsified testing data. Akorn filed suit against Fresenius one day after the company walked away from a $4.75 billion deal to acquire Akorn. Fresenius cited an investigation that found material breaches of […]

Filed Under: Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Akorn, Fresenius

Fresenius abandons $4.3B Akorn merger, citing data integrity probe

April 23, 2018 By Sarah Faulkner

Akorn

Fresenius (ETR:FRE) is walking away from a $4.3 billion merger with U.S. generic drugmaker, Akorn Inc. (NSDQ:AKRX), citing an investigation that found material breaches of FDA data integrity requirements relating to Akorn’s operations. Fresenius said in a statement that it offered to delay its decision to give Akorn time to compete its own investigation, but Akorn turned […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Akorn, Fresenius

FDA’s Gottlieb updates on IV bag shortages after Hurricane Maria

January 17, 2018 By Sarah Faulkner

FDA

FDA commissioner Dr. Scott Gottlieb expects that the shortage of IV fluids caused by Hurricane Maria in Puerto Rico will improve in the coming weeks and months, according to a statement issued by the agency yesterday. The regulatory chief said that the FDA is working with manufacturers like Baxter (NYSE:BAX) and B. Braun to import products […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: B. Braun Medical, Baxter International, Fresenius, Grifols

FDA wants Fresenius to hire a consultant to fix long-standing CGMP woes

January 3, 2018 By Sarah Faulkner

Fresenius Kabi

The FDA issued a warning letter to one of Fresenius‘ (NYSE:FMS) drug manufacturing plants in India last week, citing concerns that the company has not adequately addressed a sterility problem noted during previous inspections. It’s not the first time that the Kalyani, India-based manufacturing firm has been hit with a warning. In its letter to […]

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: Fresenius

Fresenius Kabi to invest $100m in North Carolina manufacturing site

November 21, 2017 By Sarah Faulkner

Fresenius Kabi

Fresenius (NYSE:FMS) business group Fresenius Kabi said today that it plans to invest more than $100 million over the next five years in a Wilson, N.C.-based manufacturing site. The company’s expansion project is designed to boost the facility’s capacity to produce generic medicines in pre-filled syringes, Fresenius reported. The expansion is also slated to increase the […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Fresenius

Medtech stories we missed this week: Sept. 15, 2017

September 15, 2017 By Danielle Kirsh

missed medtech aug 4

From Acera Surgical and Telos Medical’s partnership to Xtant Medical’s 510(k) clearance, here are seven medtech stories we missed this week but thought were still worth a mention. 1. Acera Surgical partners with Telos Medical for Restrata wound matrix trial Telos Partners announced in a Sept. 14 press release that Acera Surgical has chosen Telos to […]

Filed Under: Business/Financial News, Clinical Trials, Diagnostics, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Surgical Tagged With: Acera Surgical, Contego Medical, Fresenius, medtech, OBP Medical, Pinnacle Sciences, Plusoptix, Telos Medical, Xtant Medical

Fresenius closes Merck biosimilar biz purchase

September 1, 2017 By Sarah Faulkner

Fresenius Kabi

Fresenius Kabi said today that it closed its acquisition of Merck KGaA’s biosimilars unit. The company paid €156 million at closing ($185.7 million USD) and could pay up to €500 million ($595.2 million USD) in milestone payments, which are contingent upon meeting certain drug development targets. Previously, Fresenius announced it would pay €170 million upfront ($202.4 million […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Fresenius, Merck

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS